AI Article Synopsis
- * The Th17 immune response is key in how HS develops and progresses.
- * Research by Kimball et al. shows that bimekizumab is safe and effective in treating HS, providing a new treatment option based on findings from two phase 3 studies (BE HEARD I-II).
Article Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disorder with a significant negative impact on quality of life. Th17 axis has a central role in the pathogenesis of HS. Kimball et al. demonstrated the efficacy and safety of bimekizumab in two double-blind, placebo-controlled phase 3 studies (BE HEARD I-II), adding a new targeting option to the therapeutic armamentarium of HS..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.08.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Overburdened and Undertreated: Hidradenitis Suppurativa in Skin of Color.
J Clin Aesthet Dermatol
January 2024
Ms. Sangha is a senior medical science liaison for Incyte Corporation in Wilmington, Delaware. Prior to that, she spent over a decade as a dermatology PA specializing in general, surgical, and cosmetic dermatology. She is a fellow of the American Academy of Physician Assistants in Alexandria, Virginia. She is also a Past President of the Society of Dermatology Physician Assistants.
Demographic features, clinical characteristics, and comorbid relation in hidradenitis suppurativa: a population-based study.
Front Med (Lausanne)
January 2025
Department of Dermatology, Biruni University, İstanbul, Türkiye.
Background/objective: Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting apocrine gland areas, characterized by painful nodules and abscesses that may result in sinus tracts and scarring. The global prevalence of HS is increasing due to heightened awareness, improved diagnostic methods, rising obesity rates, and higher smoking prevalence. This study aimed to describe the epidemiological, clinical, and comorbid characteristics of HS patients.
View Article and Find Full Text PDFMinimally invasive management of hidradenitis suppurativa using a 1470 nm diode laser: a step-by-step description of our technique.
BMC Surg
January 2025
Department of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Background: The management of hidradenitis suppurativa (HS) requires a multidisciplinary approach to ensure sustainable treatment results, especially in the advanced stages. Traditionally, deroofing and wide excision represented commonly employed surgical techniques. Due to the recurrent nature of HS, tissue preservation should be a relevant aspect of surgical management.
View Article and Find Full Text PDFA Death From Necrotizing Wound Infection After Cesarean Section: Resurgence of Group A Streptococcal Puerperal Sepsis.
Am J Forensic Med Pathol
January 2025
From the Department of Pathology, University of Nevada Reno School of Medicine.
Necrotizing wound infections are potentially lethal complications of surgeries, including cesarean deliveries. A 32-year-old female with obesity and hidradenitis suppurativa (HS) underwent uncomplicated cesarean section. Four days later, she developed abdominal pain and imaging showed ascites; she was treated with antibiotics.
View Article and Find Full Text PDFImprovement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
Cureus
December 2024
Department of Dermatology, Duke University Medical Center, Durham, USA.
Folliculitis decalvans (FD) is a chronic inflammatory alopecia characterized by painful, scarring lesions and recurrent flares, often complicated by secondary bacterial infections. Despite the use of topical and systemic anti-inflammatory or antimicrobial therapies, FD remains challenging to manage, with limited therapeutic advancements. We report a case of recalcitrant FD in a man in his 40s who experienced significant symptom improvement and hair regrowth following the initiation of tirzepatide for weight management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!